Fliszar Kyle A, Foster Natalie
Merck and Co., Inc. Merck Manufacturing Division, West Point, PA 19486, United States.
Int J Pharm. 2008 Mar 3;351(1-2):127-32. doi: 10.1016/j.ijpharm.2007.09.023. Epub 2007 Sep 25.
A continuous dissolution/absorption system using a hexadecane membrane (HDM) as the permeation measurement has been examined for three distinct formulations of metformin hydrochloride. This system was used to correlate the absorption rate of metformin through the membrane after release from the dosage form to rate of appearance of metformin in the plasma from the same formulations. These correlations were then used to make predictions of the in vivo plasma profile for each formulation. Successful predictions of AUC were accomplished for both immediate release and extended release formulations of metformin hydrochloride.
一种使用十六烷膜（HDM）进行渗透测量的连续溶解/吸收系统，已针对三种不同的盐酸二甲双胍制剂进行了研究。该系统用于将二甲双胍从剂型中释放后透过膜的吸收速率与相同制剂在血浆中二甲双胍的出现速率相关联。然后利用这些相关性对每种制剂的体内血浆曲线进行预测。对于盐酸二甲双胍的速释和缓释制剂，均成功预测了AUC。
